DMAC
Price
$8.67
Change
+$0.80 (+10.17%)
Updated
Oct 20 closing price
Capitalization
467.54M
21 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.58
Change
+$0.16 (+6.61%)
Updated
Oct 20 closing price
Capitalization
396.24M
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMAC vs EDIT

DMAC vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMAC vs. EDIT commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Hold and EDIT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DMAC with price predictions
Oct 20, 2026

DMAC in upward trend: 10-day moving average broke above 50-day moving average on September 22, 2026

The 10-day moving average for DMAC crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where DMAC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 77 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

DMAC moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +14.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 216 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 123 of 157 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.

Bearish Trend Analysis

The 10-day RSI Indicator for DMAC moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.

The Moving Average Convergence Divergence Histogram (MACD) for DMAC turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 39 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.195) is normal, around the industry mean (3.009). P/E Ratio (-12.042) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for EDIT with price predictions
Oct 20, 2026

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.764) is normal, around the industry mean (3.009). P/E Ratio (-3.909) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
DMAC vs EDIT: Fundamental Ratings
DMAC
EDIT
OUTLOOK RATING
1..100
8784
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3977
P/E GROWTH RATING
1..100
6827
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (54) in the Biotechnology industry is in the same range as DMAC (70). This means that EDIT’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that DMAC’s stock grew somewhat faster than EDIT’s over the last 12 months.

DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as EDIT (99). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

DMAC's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for EDIT (77). This means that DMAC’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's P/E Growth Rating (27) in the Biotechnology industry is somewhat better than the same rating for DMAC (68). This means that EDIT’s stock grew somewhat faster than DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (DMAC: $8.67 vs. EDIT: $2.58)
Brand notoriety: DMAC and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 78% vs. EDIT: 63%
Market capitalization -- DMAC: $467.54M vs. EDIT: $396.24M
DMAC [@Biotechnology] is valued at $467.54M. EDIT’s [@Biotechnology] market capitalization is $396.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, DMAC is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 8 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • DMAC’s TA Score: 8 bullish, 3 bearish.
  • EDIT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than EDIT.

Price Growth

DMAC (@Biotechnology) experienced а +10.87% price change this week, while EDIT (@Biotechnology) price change was +5.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 11, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMAC
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
USTC.X0.0050370.000180
+3.70%
TerraClassicUSD cryptocurrency
QTUM.X0.8777450.016629
+1.93%
Qtum cryptocurrency
HBAR.X0.0842620.001327
+1.60%
Hedera cryptocurrency
BTCST.X0.0101710.000141
+1.41%
Bitcoin Standard Hashrate Token cryptocurrency
SANTOS.X0.477821-0.000207
-0.04%
Santos FC Fan Token cryptocurrency

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+10.17%
VIR - DMAC
45%
Loosely correlated
+5.19%
EDIT - DMAC
45%
Loosely correlated
+6.61%
TSHA - DMAC
44%
Loosely correlated
+4.31%
ANNX - DMAC
42%
Loosely correlated
-4.49%
SLDB - DMAC
41%
Loosely correlated
+8.11%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+6.61%
BEAM - EDIT
66%
Closely correlated
+3.06%
CRSP - EDIT
63%
Loosely correlated
-0.32%
PRME - EDIT
62%
Loosely correlated
+2.35%
VYGR - EDIT
60%
Loosely correlated
+6.83%
SLDB - EDIT
60%
Loosely correlated
+8.11%
More